SCHEMBL6823308

SCHEMBL6823308

CCOC(=O)C1CCCN(C(=O)Nc2c(C)cc3c(c2C)c2ccccc2n3C(C)C)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 3/20 0.62
HTT P42858 1/20 0.56
SHMT2 P34897 1/20 0.53
TSHR P16473 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 1/20 0.47
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.45
TP53 P04637 1/20 0.45
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6828937 0.89 NPY5R (0.67) NPY5RHTTSHMT2KMT2AALDH1A1
SCHEMBL6823362 0.88 NPY5R (0.66) NPY5RHTTSHMT2KMT2AHPGD
SCHEMBL6826749 0.87 NPY5R (0.65) NPY5RHTTSHMT2TSHRKMT2A
SCHEMBL6826986 0.87 NPY5R (0.67) NPY5RHTTSHMT2TSHRALDH1A1
SCHEMBL6826597 0.87 NPY5R (0.64) NPY5RHTTSHMT2KMT2AALDH1A1
SCHEMBL6826590 0.84 NPY5R (0.60) NPY5RTSHRKMT2AALDH1A1SMN1; SMN2
SCHEMBL6829275 0.84 NPY5R (0.69) NPY5RHTTTSHRKMT2AALDH1A1
SCHEMBL7087839 0.83 NPY5R (0.58) NPY5RHTTSHMT2KMT2ANPC1
SCHEMBL6829075 0.81 NPY5R (0.66) NPY5RHTTKMT2ASMN1; SMN2HPGD
SCHEMBL6829168 0.77 NPY5R (1.00) NPY5RHTTTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067999-A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands ASTRAZENECA AB (SE) 2004-04-08 US disclosed
EP-1358157-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS AstraZeneca AB (SE) 2003-11-05 EP disclosed
WO-2002051806-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067999-A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands NPY5R, NPY1R, NPY2R NPY5R 1/4885HTT 2778/4885SHMT2 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.